Results 51 to 60 of about 354 (112)

Blood‐Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations

International Journal of Cancer, Volume 159, Issue 4, Page 1028-1041, 15 August 2026.
Early detection of colorectal cancer via population‐based screening programs can reduce incidence and mortality, but current screening approaches are limited. This systematic review evaluated the screening potential of blood‐based circulating tumor DNA assays in asymptomatic screening populations.
Caroline Ledertoug Kahn, Maria Wissing Rasmussen, Jakob Kleif, Inge Søkilde Pedersen, Christina Therkildsen   +4 more
wiley   +1 more source

Exploring the Predictive Value of Circulating Cell-Free DNA Within a Multiparameter Panel for Hepatocellular Carcinoma Detection

Life
Background: Hepatocellular carcinoma (HCC) is one of the most common and deadliest cancers worldwide. Alpha-fetoprotein (AFP), a widely used and accessible tumoral marker, has limited performance in the early detection of HCC among high-risk populations.
Ioana Manea, Speranta Maria Iacob, Razvan Iacob, Alina-Veronica Ghionescu, Andrei Sorop, Roxana Elena Saizu, Daria-Ana-Arina Gheorghe, Delia Prisecariu, Simona Olimpia Dima, Liliana Simona Gheorghe   +9 more
doaj   +1 more source

Circulating Mitochondrial DNA Measures Across Malignancies: Diagnostic Accuracy and Prognostic Associations

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Background Circulating mitochondrial DNA is being investigated as a liquid‐biopsy biomarker because of its high copy number and release during cellular stress. However, diagnostic estimates vary across tumor types and assays, and prognostic studies have measured both cell‐free mtDNA and cellular blood‐derived mtDNA, which are not analytically ...
Ziying Zhang, Ying Jiang, Yu Gong, Hui Xie, Yaqian Han, Peng Chen   +5 more
wiley   +1 more source

Applications of Artificial Intelligence in Cancer Diagnosis and Treatment

Cancer Medicine, Volume 15, Issue 8, August 2026.
This review explores how AI and multimodal data fusion transform oncology through enhanced screening, precision diagnosis, and personalized therapy. By dissecting core challenges—including data bias and explainability—it provides a strategic framework for the digital transformation and ethical implementation of AI in clinical cancer care.
Yifeng Xie, Zixuan Wang, Zhiwen Zeng, Tongyao Xin, Shaofei Yuan, Feiwei Qin, Zhonglin Chen   +6 more
wiley   +1 more source

Liquid Biopsy in Early Screening of Cancers: Emerging Technologies and New Prospects

Biomedicines
Liquid biopsy is moving beyond mutation-centric assays to multimodal frameworks that integrate cell-free DNA (cfDNA) signals with additional analytes such as circulating tumor cells (CTCs) and extracellular vesicles (EVs).
Hanyu Zhu, Zhenyu Li, Kunxin Xie, Sajjaad Hassan Kassim, Cheng Cao, Keyu Huang, Zipeng Lu, Chenshan Ma, Ying Li, Kuirong Jiang, Lingdi Yin   +10 more
doaj   +1 more source

Abstract 3350: Cell-free DNA fragmentation patterns analyzed in over 15000 cancer patients reveal changes associated with tumor somatic mutations and result in improved sensitivity and specificity of somatic variant detection

, 2017
Background: Cell-free DNA (cfDNA) isolated from plasma consists of DNA fragments surviving clearance of dying cells and bloodstream trafficking. In cancer, these fragments carry the footprint of tumor somatic variation as well as its microenvironment ...
AmirAli Talasaz, Diana Abdueva, Helmy Eltoukhy, Darya Chudova   +3 more
core   +1 more source

An Epstein‐Barr Virus Nuclear Antigen 1 (EBNA1) Serology Test Strip for Nasopharyngeal Carcinoma Risk Screening

Journal of Medical Virology, Volume 98, Issue 8, August 2026.
ABSTRACT Antibodies to Epstein‐Barr virus (EBV) proteins can predict nasopharyngeal carcinoma (NPC) risk. We previously defined a prototype EBNA1 protein panel and multiplex immunoblot assay that distinguishes NPC risk several years pre‐diagnosis.
Benjamin E. Warner, Japan Patel, Rebecca Satterwhite, Renwei Wang, Jennifer Adams‐Haduch, Woon‐Puay Koh, Jian‐Min Yuan, Kathy H. Y. Shair   +7 more
wiley   +1 more source

Liquid biopsy biomarkers for early detection of gastrointestinal cancers: Current landscape and emerging technologies

Clinical and Translational Medicine
Early detection of gastrointestinal (GI) cancers remains a critical unmet clinical need, as most patients are diagnosed at advanced stages when prognosis is poor.
Muhammad Anees, Christopher Sherry, Hyun Y. Park, Erin E. Grayhack, Arul Goel, Alisha F. Khan, Ashten Omstead, David L. Bartlett, Ajay Goel, Neda Dadgar, Patrick L. Wagner, Ali H. Zaidi   +11 more
doaj   +1 more source

Fragmentomics in Pediatric Genetics: A New Frontier for Non-invasive Diagnosis of Rare Congenital and Metabolic Disorders

Cell-free DNA (cfDNA) circulating in plasma is fragmented non-randomly, and the resulting patterns carry information about the cells and tissues from which the molecules were released.
Elena Moschüring-Alieva, Stefan Bittmann, Elisabeth Luchter   +2 more
core   +1 more source

Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer

, 2021
Cell-free DNA (cfDNA) analysis using liquid biopsies is a non-invasive method to gain insights into the biology, therapy response, mechanisms of acquired resistance and therapy escape of various tumors. While it is well established that individual cancer
Holger Sültmann, Simone Bauer, Arlou Kristina Angeles, Florian Janke, Petros Christopoulos, Anja Lisa Riediger   +5 more
core   +1 more source